Jove
Visualize
Contact Us

Related Experiment Videos

Lenalidomide: patient management strategies.

Mohamad A Hussein1

  • 1Multiple Myeloma Research Program, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. husseim@ccf.org

Seminars in Hematology
|December 14, 2005
PubMed
Summary

Lenalidomide, a thalidomide analogue, shows high response rates and a better safety profile. This review covers its use, side effects like peripheral neuropathy and deep venous thrombosis (DVT), and management strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Blood cancer journal·2018
Same author

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Clinical cancer research : an official journal of the American Association for Cancer Research·2017
Same author

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Leukemia & lymphoma·2015
Same author

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Cancer medicine·2014
Same author

Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.

American journal of hematology·2013
Same author

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

American journal of hematology·2013
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Thalidomide management necessitates careful side effect monitoring for therapeutic success.
  • Lenalidomide, a thalidomide analogue, demonstrates promising efficacy with an improved toxicity profile.

Purpose of the Study:

  • To describe Cleveland Clinic's experience with lenalidomide therapy.
  • To review management strategies for lenalidomide-associated toxicities, including peripheral neuropathy and deep venous thrombosis (DVT).

Main Methods:

  • Review of lenalidomide use, alone and in combination regimens.
  • Analysis of lenalidomide-associated side effects and myelosuppression.

Main Results:

  • Lenalidomide shows impressive response rates.
  • Peripheral neuropathy and DVT are key toxicities.
  • Low-dose aspirin mitigated DVT in combination therapy.

Conclusions:

  • Lenalidomide offers a favorable therapeutic profile compared to thalidomide.
  • Proactive management of lenalidomide toxicities is crucial for patient outcomes.
  • Strategies for recognizing and managing myelosuppression are essential.

Related Experiment Videos